- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Retail Earnings and Sales to Improve in Q4: Analyst
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- 3 Software Stock Picks from Lazard's Senior Analyst
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
MOST SHARED
- Chinese Overcapacity is Worsening, EU Chamber Warns
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- The Executive Job Search
- Gold Retreats from New High Above $1,194
- Hyundai-Kia Targets Rapid China Growth in 2010
- China Unveils Carbon Target Ahead of Copenhagen
- Black Friday: Bargain or Bust?
- Wal-Mart Price Pressure Hurts China Workers: Report
- Oil Friday
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Fannie Mae to Tighten Lending Standards: Report
- Share Trading on London Stock Exchange Resumes
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- UK Retail Sales Pick Up in Nov., Strong Dec. Seen
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
RSS FEED
CNBC Stock Blog
Text Size 
Pharmaceutical companies may not have been immune to the weak economy, but its effects on pharma “have not been as dramatic as some of the other sectors,” said Catherine Arnold, senior pharmaceuticals analyst at Credit Suisse.
Pfizer reported a better-than-expected profit as cost-cutting helped offset sharply lower sales of its cholesterol fighter and its anti-smoking drug on Tuesday morning, while Bristol-Myers Squibb said its profit slipped 3 percent, as negative foreign exchange factors and falling sales of its cancer medicine more than offset higher revenue from other medicines.
“Although neither [Pfizer or Bristol-Myers Squibb] are necessarily the major pharmaceuticals that produce anti-viral medicine for pandemics, big drug companies do play a role in having an important mission,” said Arnold.
She named her favorite makers of anti-viral drugs.
Arnold's Picks:
Roche
Gilead [GILD
Loading...
()
]
GlaxoSmithKline [GSK
Loading...
()
]
Arnold also said she has an outperform rating on Pfizer [PFE
Loading...
()
] and a neutral rating on Bristol-Myers Squibb [BMY
Loading...
()
].
More Swine Flu News From CNBC.com
- Companies Start Initial Work on Vaccine
- Deathtoll Rises in Mexico
- Flu Impact: Latin America Stock IndexesDisclosure:
Arnold does not own shares of any of the companies mentioned above.
Data is a real-time snapshot *Data is delayed at least 15 minutes